Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Saruplase. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Saruplase. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Saruplase. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Saruplase is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Saruplase. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Saruplase. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Saruplase is combined with Obinutuzumab. |
| Rivaroxaban | Saruplase may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Saruplase is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Saruplase. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Saruplase. |
| Urokinase | Urokinase may increase the anticoagulant activities of Saruplase. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of Saruplase. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Saruplase. |
| Aprotinin | The therapeutic efficacy of Saruplase can be decreased when used in combination with Aprotinin. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Saruplase. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Saruplase. |
| Quinine | The therapeutic efficacy of Saruplase can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of Saruplase can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with Saruplase. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with Saruplase. |
| Pentoxifylline | The therapeutic efficacy of Saruplase can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | Pentosan polysulfate may increase the anticoagulant activities of Saruplase. |
| Levocarnitine | The therapeutic efficacy of Saruplase can be increased when used in combination with Levocarnitine. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of Saruplase. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of Saruplase. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of Saruplase. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with Saruplase. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of Saruplase. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of Saruplase. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of Saruplase. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Saruplase. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Saruplase. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of Saruplase. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of Saruplase. |
| Zeranol | Zeranol may decrease the anticoagulant activities of Saruplase. |
| Equol | Equol may decrease the anticoagulant activities of Saruplase. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of Saruplase. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of Saruplase. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of Saruplase. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of Saruplase. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of Saruplase. |
| Estradiol cypionate | Estradiol cypionate may decrease the anticoagulant activities of Saruplase. |
| Estradiol valerate | Estradiol valerate may decrease the anticoagulant activities of Saruplase. |
| Biochanin A | Biochanin A may decrease the anticoagulant activities of Saruplase. |
| Formononetin | Formononetin may decrease the anticoagulant activities of Saruplase. |
| Estriol | Estriol may decrease the anticoagulant activities of Saruplase. |
| Icosapent | The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Saruplase. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with Saruplase. |
| Indomethacin | The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Saruplase. |
| Nabumetone | The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Saruplase. |
| Ketorolac | The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Saruplase. |
| Tenoxicam | The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Saruplase. |
| Celecoxib | The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Saruplase. |
| Tolmetin | The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Saruplase. |
| Rofecoxib | The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Saruplase. |
| Piroxicam | The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Saruplase. |
| Fenoprofen | The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Saruplase. |
| Valdecoxib | The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Saruplase. |
| Diclofenac | The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Saruplase. |
| Sulindac | The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Saruplase. |
| Flurbiprofen | The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Saruplase. |
| Etodolac | The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Saruplase. |
| Mefenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Saruplase. |
| Naproxen | The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Saruplase. |
| Sulfasalazine | The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Saruplase. |
| Phenylbutazone | The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Saruplase. |
| Meloxicam | The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Saruplase. |
| Carprofen | The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Saruplase. |
| Diflunisal | The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Saruplase. |
| Salicylic acid | The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Saruplase. |
| Meclofenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Saruplase. |
| Oxaprozin | The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Saruplase. |
| Ketoprofen | The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Saruplase. |
| Balsalazide | The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Saruplase. |
| Olsalazine | The risk or severity of bleeding can be increased when Olsalazine is combined with Saruplase. |
| Lumiracoxib | The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Saruplase. |
| Magnesium salicylate | The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Saruplase. |
| Salsalate | The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Saruplase. |
| Choline magnesium trisalicylate | The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Saruplase. |
| Antrafenine | The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Saruplase. |
| Aminophenazone | The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Saruplase. |
| Antipyrine | The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Saruplase. |
| Tiaprofenic acid | The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Saruplase. |
| Etoricoxib | The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Saruplase. |
| Taxifolin | The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Saruplase. |
| Oxyphenbutazone | The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Saruplase. |